Dupixent front and center of Sanofi's lofty immunology ambitions

French drugmaker Sanofi (Euronext: SAN) held an investor event this week to outline its ambitions in the immunology space, including the goal to more than quadruple sales in this space by 2030.

The focus of the event was on Dupixent (dupilumab) as a key growth driver, along with Sanofi’s broader pipeline, underlining the importance of dermatological, respiratory and gastrointestinal diseases as priority therapeutic areas for the company.

Sanofi has raised the Dupixent sales peak ambition to more than 13 billion euros ($14.4 billion), where in 2021 the drug’s revenue was 5.25 billion euros. This new target does not include potential for additional sales ambition upgrade from chronic obstructive pulmonary disease (COPD), with pivotal readouts anticipated in 2023.